WEBULL

Is PTC Therapeutics (PTCT) Cheap On Fast Track News For PTC518?

Simply Wall St · 1d ago

PTC Therapeutics (PTCT) is back in focus after its PTC518 Huntington’s disease program received Fast Track designation, a regulatory milestone that can influence how investors view its rare neurology pipeline.

See our latest analysis for PTC Therapeutics.

At a share price of $78.59, PTC Therapeutics has a 90 day share price return of 8.67%, while its 1 year total shareholder return of 65% suggests stronger momentum over a longer window despite recent short term weakness. The Fast Track news on PTC518 sits alongside this backdrop and shapes how investors weigh the company’s rare disease pipeline against its recent share price path.

If breakthroughs in rare disease treatments interest you, this could be a useful moment to see what else is out there and scan 39 healthcare AI stocks

For PTC Therapeutics, a 1 year total return of 65% alongside a recent pullback raises a simple tension: is the stock now echoing progress in the rare disease business, or mostly swinging with sentiment around headlines like Fast Track news?

Most Popular Narrative: 16.3% Undervalued

On the latest narrative view, PTC Therapeutics’ fair value of $93.93 sits meaningfully above the recent $78.59 close, framing the Fast Track update within a broader rare disease story.

Robust late-stage pipeline progress, including 2 NDAs under FDA review (vatiquinone for Friedreich's ataxia and Translarna), and upcoming potential Phase 3 entry for PTC518 in Huntington's (partnered with Novartis), increases the probability of further product launches, expanding addressable markets, and diversifying near

and medium-term revenue streams, thereby improving overall revenue stability and future earnings visibility.

Read the complete narrative.

Curious what sits behind that projected value gap for PTC Therapeutics? Revenue build, margin trajectory and the earnings multiple all pull in different directions. The narrative connects them into one coherent valuation story.

Result: Fair Value of $93.93 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, for PTC Therapeutics the narrative could be knocked off course if Sephience uptake or pricing falls short, or if Translarna access in Europe tightens further.

Find out about the key risks to this PTC Therapeutics narrative.

Another View: PTC Therapeutics Through a Sales Multiple Lens

The SWS DCF model suggests PTC Therapeutics is heavily undervalued, with a fair value of $253.95 versus the $78.59 share price. On a sales multiple, though, the picture is more grounded: the current P/S of 7.9x is only slightly below peers at 8.3x and well above a fair ratio of 4.8x. This highlights meaningful rerating risk if optimism cools.

For readers weighing which signal to lean on, it helps to see exactly how the numbers stack up in the detailed valuation work, then decide which set of assumptions feels more realistic for PTC Therapeutics’ rare disease story. See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:PTCT P/S Ratio as at Jul 2026
NasdaqGS:PTCT P/S Ratio as at Jul 2026

Next Steps

If this PTC Therapeutics story feels finely balanced between promise and pressure, consider reviewing the data promptly, weighing both sides and examining the 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond PTC Therapeutics?

If you want more context around PTC Therapeutics and similar opportunities, use the Simply Wall Street Screener to compare different types of stocks and stay informed about potential opportunities.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.